Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adam Corner

Showing results (11-20 of 23) with videos related to

Pageof 3
Sort By:
Bone Marrow Transplantation|January 5, 2024
Persistent IDH mutations are not associated with increased relapse or death in patients with IDH-mutated acute myeloid leukemia undergoing allogeneic hematopoietic cell transplant with post-transplant cyclophosphamideNiveditha Ravindra, Laura W Dillon, Gege Gui, et al.
Medrxiv : the Preprint Server for Health Sciences|September 4, 2023
Persistent <i>IDH</i> mutations are not associated with increased relapse or death in patients with <i>IDH</i>-mutated acute myeloid leukemia undergoing allogeneic hematopoietic cell transplant with post-transplant cyclophosphamideNiveditha Ravindra, Laura W Dillon, Gege Gui, et al.
Global Environmental Change : Human and Policy Dimensions|April 4, 2017
'Green' on the ground but not in the air: Pro-environmental attitudes are related to household behaviours but not discretionary air travelIan Alcock, Mathew P White, Tim Taylor, et al.
Medrxiv : the Preprint Server for Health Sciences|February 6, 2026
Whole Genome Sequencing Informed Patient Personalized Measurable Residual Disease Assays for Acute Myeloid LeukemiaNiveditha Ravindra, Justin Lack, Clifton L Dalgard, et al.
Leukemia|July 30, 2022
Droplet digital PCR for the detection of second-generation tyrosine kinase inhibitor-resistant BCR::ABL1 kinase domain mutations in chronic myeloid leukemiaSimona Soverini, Sara De Santis, Margherita Martelli, et al.
Leukemia|May 23, 2024
Recommendations from the AML molecular MRD expert advisory boardStuart Scott, Alison Devonshire, Richard Dillon, et al.
JCO Precision Oncology|June 26, 2025
Minimum Technical Preanalytical, Patient, and Clinical Context Data Elements for Cerebrospinal Fluid Liquid Biopsy: Recommendations for Public Database SubmissionsStephen J Bagley, Nike Beaubier, Leonora Balaj, et al.
JCO Precision Oncology|May 11, 2026
Generic Protocols for the Analytical Validation of Next-Generation Sequencing-Based Circulating Tumor DNA Assays, Version 2.0Angela Silvestro, Jonathan Baden, Kevin Billings, et al.
Clinical Epigenetics|May 19, 2026
Development, characterization, and inter-laboratory validation of methylated human cell free DNA candidate reference materialsZhiyong He, Yves Konigshofer, Russell Garlick, et al.
Bone Marrow Transplantation|October 18, 2024
Measurable residual FLT3 tyrosine kinase domain mutations before allogeneic transplant for acute myeloid leukemiaPranay S Hegde, Georgia Andrew, Gege Gui, et al.
Pageof 3

Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
Bone Marrow Transplantation|January 5, 2024
Persistent IDH mutations are not associated with increased relapse or death in patients with IDH-mutated acute myeloid leukemia undergoing allogeneic hematopoietic cell transplant with post-transplant cyclophosphamideNiveditha Ravindra, Laura W Dillon, Gege Gui, et al.
Medrxiv : the Preprint Server for Health Sciences|September 4, 2023
Persistent <i>IDH</i> mutations are not associated with increased relapse or death in patients with <i>IDH</i>-mutated acute myeloid leukemia undergoing allogeneic hematopoietic cell transplant with post-transplant cyclophosphamideNiveditha Ravindra, Laura W Dillon, Gege Gui, et al.
Global Environmental Change : Human and Policy Dimensions|April 4, 2017
'Green' on the ground but not in the air: Pro-environmental attitudes are related to household behaviours but not discretionary air travelIan Alcock, Mathew P White, Tim Taylor, et al.
Medrxiv : the Preprint Server for Health Sciences|February 6, 2026
Whole Genome Sequencing Informed Patient Personalized Measurable Residual Disease Assays for Acute Myeloid LeukemiaNiveditha Ravindra, Justin Lack, Clifton L Dalgard, et al.
Leukemia|July 30, 2022
Droplet digital PCR for the detection of second-generation tyrosine kinase inhibitor-resistant BCR::ABL1 kinase domain mutations in chronic myeloid leukemiaSimona Soverini, Sara De Santis, Margherita Martelli, et al.
Leukemia|May 23, 2024
Recommendations from the AML molecular MRD expert advisory boardStuart Scott, Alison Devonshire, Richard Dillon, et al.
JCO Precision Oncology|June 26, 2025
Minimum Technical Preanalytical, Patient, and Clinical Context Data Elements for Cerebrospinal Fluid Liquid Biopsy: Recommendations for Public Database SubmissionsStephen J Bagley, Nike Beaubier, Leonora Balaj, et al.
JCO Precision Oncology|May 11, 2026
Generic Protocols for the Analytical Validation of Next-Generation Sequencing-Based Circulating Tumor DNA Assays, Version 2.0Angela Silvestro, Jonathan Baden, Kevin Billings, et al.
Clinical Epigenetics|May 19, 2026
Development, characterization, and inter-laboratory validation of methylated human cell free DNA candidate reference materialsZhiyong He, Yves Konigshofer, Russell Garlick, et al.
Bone Marrow Transplantation|October 18, 2024
Measurable residual FLT3 tyrosine kinase domain mutations before allogeneic transplant for acute myeloid leukemiaPranay S Hegde, Georgia Andrew, Gege Gui, et al.
Pageof 3